'Exciting Era' Underway

May 1, 2003
Fred Wilson

Fred Wilson is a medical writer based in Syracuse, New York.

San Francisco -- Patients with moderate to severe psoriasis can receive efalizumab (Anti-CD11a) continually with no increased toxicity for approximately one year, an ongoing open-label trial shows.

Related Content:

News